Drug intelligence / Profile preview

68Ga-010

Development stage: Preclinical
Lead developer: Healthytide Biotechnology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-010 is a radiopharmaceutical imaging agent developed by Hangzhou Healthytide Biotechnology Co., LTD. It is a gallium-68 labeled integrin receptor probe designed for diagnostic purposes, particularly in patients with Non-Small Cell Lung Cancer (NSCLC). Integrin receptors are heterodimeric transmembrane proteins involved in cell adhesion and signaling, and 68Ga-010 targets these receptors to aid in diagnostic imaging.

Targets

Neuraminidase

Beyond the preview

Go deeper on 68Ga-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-010.

Explore the full profile